Cassava Sciences (NASDAQ:FLNA – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.
Earnings and Valuation
This table compares Cassava Sciences and VYNE Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.87 |
| VYNE Therapeutics | $570,000.00 | 38.91 | -$26.48 million | ($0.38) | -1.75 |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Cassava Sciences and VYNE Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
| VYNE Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 257.14%. Given Cassava Sciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cassava Sciences is more favorable than VYNE Therapeutics.
Profitability
This table compares Cassava Sciences and VYNE Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cassava Sciences | N/A | -53.90% | -34.20% |
| VYNE Therapeutics | -4,726.21% | -70.42% | -63.46% |
Insider and Institutional Ownership
38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Cassava Sciences has a beta of -0.71, indicating that its share price is 171% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
Summary
Cassava Sciences beats VYNE Therapeutics on 8 of the 13 factors compared between the two stocks.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
